Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

The Serum Level of Insulin Growth Factor-1 and Insulin Growth Factor Binding Protein-3 in Children with Henoch-Schönlein Purpura

  • Kim, Hee Jin (Department of Pediatrics, CHA Bundang Medical Center, CHA University) ;
  • Jung, Su Jin (Department of Pediatrics, CHA Bundang Medical Center, CHA University) ;
  • Lee, Jun Ho (Department of Pediatrics, CHA Bundang Medical Center, CHA University)
  • Received : 2016.02.05
  • Accepted : 2016.03.30
  • Published : 2016.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We investigated whether serum levels of insulin growth factor-1 (IGF-1) and insulin growth factor binding protein-3 (IGFBP-3) are valuable in predicting clinical outcomes or are correlated with other laboratory findings in children with Henoch-$Sch{\ddot{o}}nlein$ purpura (HSP). Methods: We examined 27 children who were consecutively admitted to our hospital with HSP between January 2011 and February 2012. Blood tests (C-reactive protein, white blood cell count, platelet count, erythrocyte sedimentation rate, albumin, immunoglobulin A, complement C3, antineutrophil cytoplasmic antibody, IGF-1, IGFBP-3) and urine tests were performed upon admission. IGF-1 and IGFBP-3 were resampled in the recovery phase. Controls included 473 children whose IGF-1 and IGFBP-3 were sampled for evaluating their growth, at the outpatient department of pediatric endocrinology in our hospital. IGF-1 and IGFBP-3 were compared between the HSP children and controls, and between the acute and recovery phases in HSP children. The ability of these values to predict clinical outcomes including renal involvement was analyzed using bivariate logistic regression analysis (BLRA). Results: IGF-1 and IGFBP-3 were not different between the HSP children and controls ($148.7{\pm}117.6$ vs. $69.2{\pm}96.9$, P=0.290: $3465.9{\pm}1290.9$ vs. $3597.2{\pm}1,127.6$, P=0.560, respectively). There was no significant difference in IGF-1 or IGFBP-3 between acute and recovery phases. Based on the BLRA, no variable, including IGF-1 and IGFBP-3, could predict clinical outcomes including the presence of nephritis Conclusion: We concluded that IGF-1 and IGFBP-3 do not predict clinical outcomes of HSP, including renal involvement, in this study.

Keywords

References

  1. Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormala T, Nuutinen M. Outcome of Henoch-Schonlein nephritis with nephritic-range proteinuria. Clin Nephrol 2003;60:80-4. https://doi.org/10.5414/CNP60080
  2. Yildiz B, Kural N, Aydin B, Colak O. Increased serum levels of insulinlike growth factor (IGF)-1 and IGF-binding protein-3 in Henoch-Schonlein purpura. Tohoku J Exp Med 2008;214:333-40. https://doi.org/10.1620/tjem.214.333
  3. Ru L, Abudouhaer A, Guo YF. Clinical significance of serum levels of IGF-1 and IGFBP-3 in children with Henoch-Schonlein purpura or Henoch-Schonlein purpura nephritis. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:1009-13.
  4. Lin CY, Yang YH, Lee CC, Huang CL, Wang LC, Chiang BL. Thrombopoietin and interleukin-6 levels in Henoch-Schonlein purpura. J Microbiol Immunol Infect 2006;39:476-82.
  5. Ha TS. The role of tumor necrosis factor-alpha in Henoch-Schonlein purpura. Pediatr Nephrol 2005;20:149-53. https://doi.org/10.1007/s00467-004-1726-3
  6. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Theumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33:114-21.
  7. Saulsbury FT. Epidermiology of Henoch-Schonlein purpura. Cleve Clin J Med 2002;69:187-9.
  8. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 2010;95:877-82. https://doi.org/10.1136/adc.2009.182394
  9. Kawasaki Y, Ono A, Ohara S, Suzuki Y, Suyama K, Suzuki J, et al. Henoch-Schonlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci 2013;59:15-26. https://doi.org/10.5387/fms.59.15
  10. Shin JI, Park JM, Shin YH, Lee JS, Jeong JH, Kim HS. Serum IgA/C3 ratio may be a useful marker of disease activity in severe Henoch-Schonlein nephritis. Nephron Clin Pract 2005;1012:72-8.
  11. Balaram SK, Agrawal DK, Edwards JD. Insulin like growth factor-1 activates nuclear factor-${\kappa}B$ and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells. Cardiovasc Surg 1999;7:91-7. https://doi.org/10.1016/S0967-2109(98)00044-1
  12. Tonshoff B, Kaskel FJ, Moore LC. Effects of insulin-like growth factor I on the renal juxtamedullary microvasculature. Am J Physiol Renal Physiol 1998;274:120-8.
  13. Rossert J, Terraz-Durasnel C, Brideau G. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy. Diabetes Metab 2000;26(suppl 4):16-24.
  14. Oldroyd SD, Miyamoto Y, Moir A, Johnson TS, El-Nahas AM, Haylor JL. An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy. Am J Physio Renal Physiol 2006;290:695-702. https://doi.org/10.1152/ajprenal.00058.2005
  15. Ece A, Kelekci S, Kocamaz H, Hekimoglu A, Balik H, Yolbas I, et al. Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch-Schonlein purpura. Clin Rheumatol 2008;27:163-9. https://doi.org/10.1007/s10067-007-0671-5
  16. Chen T, Guo ZP, Zhang YH, Gao Y, Liu HJ, Li JY. Elevated serum heme oxygenase-1 and insulin-like growth factor-1 levels in patients with Henoch-Schonlein purpura. Rheumatol Int 2011;31:321-6. https://doi.org/10.1007/s00296-009-1254-3
  17. Ge W, Wang HL, Sun RP. Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schonlein purpura nephritis in children. Eur J PEdiatr 2014;173:213-8. https://doi.org/10.1007/s00431-013-2150-0